Trending...
- Register Now For The 2025 Boston Neighborhood Basketball League Season - 351
- Mother's Day Wake-Up Call for Maternal Health: New Initiative Demands Better Postpartum Support
- Boston: Traffic Advisory for May 9, 2025
FAYETTEVILLE, Ark. - BostonChron -- Lineus Medical has been granted five additional international patents for its flagship product, SafeBreak® Vascular, in Korea, Brazil, Australia, India, and China. These patents strengthen Lineus Medical's intellectual property portfolio as the company continues expanding into major healthcare markets worldwide. They also mark a key milestone toward obtaining regulatory clearances and establishing distribution partnerships in these regions.
SafeBreak Vascular is the only break-away device for IV lines clinically proven to reduce IV complications1. When a harmful force is placed on the line, SafeBreak intentionally separates to remove the damaging force and protect the patient's IV. When SafeBreak separates, valves on both ends of the device close preventing medicine spills from the pump and blood loss from the patient. To replace SafeBreak, each component is unthreaded from the line, a new sterile SafeBreak is installed, and the patent's infusion is restarted. Patients avoid additional needlesticks, nurses save time, and hospitals save money1.
More on Boston Chron
"Securing these new patents is a critical step in advancing the global presence of SafeBreak," said Vance Clement, CEO of Lineus Medical. "They not only protect our product from being copied and add value to the company, they also provide us credibility in establishing relationships with new distribution partners in these countries."
About Lineus Medical:
Lineus Medical is the developer of a break-away technology that is proven to reduce IV restarts and IV complications1. Our mission is to remove the pains associated with medical lines. More information about Lineus Medical can be found at www.lineusmed.com. Follow Lineus Medical on LinkedIn, Facebook, and Instagram.
References:
1. Data on File
SafeBreak Vascular is the only break-away device for IV lines clinically proven to reduce IV complications1. When a harmful force is placed on the line, SafeBreak intentionally separates to remove the damaging force and protect the patient's IV. When SafeBreak separates, valves on both ends of the device close preventing medicine spills from the pump and blood loss from the patient. To replace SafeBreak, each component is unthreaded from the line, a new sterile SafeBreak is installed, and the patent's infusion is restarted. Patients avoid additional needlesticks, nurses save time, and hospitals save money1.
More on Boston Chron
- Boston: May 16 Traffic Advisory
- Boston: Mayor Wu Announces Expansion of Free Swim Lessons for Youth; Recognizes International Water Safety Day on May 15
- Fzata to Attend BIO International Convention 2025
- Boston: Traffic Advisory for May 14 - 24, 2025
- $1B Target by 2027 Amid eSIM, Global Roaming Expansion; $57.6M Q1 Revenue and Market Uplisting, Advancing Toward IQSTEL, Inc. (Stock Symbol: IQST)
"Securing these new patents is a critical step in advancing the global presence of SafeBreak," said Vance Clement, CEO of Lineus Medical. "They not only protect our product from being copied and add value to the company, they also provide us credibility in establishing relationships with new distribution partners in these countries."
About Lineus Medical:
Lineus Medical is the developer of a break-away technology that is proven to reduce IV restarts and IV complications1. Our mission is to remove the pains associated with medical lines. More information about Lineus Medical can be found at www.lineusmed.com. Follow Lineus Medical on LinkedIn, Facebook, and Instagram.
References:
1. Data on File
Source: Lineus Medical
0 Comments
Latest on Boston Chron
- Therapy 911 Launches Mental Health Social Network to Celebrate Mental Health Awareness Month
- Bosco's Beach Launches Vacation Rentals in Panama City Beach, Florida
- $7.8M Financing Boosts NRx's Expansion with Kadima Institute Acquisition for PTSD and Depression Care: NRx Pharmaceuticals, Inc. (Stock Symbol: NRXP)
- One Park Financial Once Again Honored with Sun Sentinel's Top Workplaces Award for the 8th Time — Achieves Best Ranking Yet in 2025
- Project STEP Returns to Symphony Hall with Free Recital, First in Over a Decade
- Cycurion Wins $33M Cybersecurity Contract for State Colleges, Also $6M from Transportation Agency: Cycurion, Inc. (Stock Symbol: CYCU) is Undervalued
- Novel 'We Won't Go Back' Published; Addresses Women's Issues
- 20/20 Foresight Acquires Winter Street Search, Expanding Financial Services Practice
- Call for Papers Deadline Approaching – Don't Miss Your Shot to Speak at the OpenSSL Conference 2025!
- Mayor Wu Announces Year Two Recipients of Un-monument | Re-monument | De-monument: Transforming Boston
- The ROS1ders Announces Recipients of 2024 ROS1+ Cancer Innovation Awards
- Mayor Wu Announces City of Boston Achieves Triple-A Bond Ratings for 12th Consecutive Year
- Boston: Supporting the Workforce Development Efforts of New and Emerging Job Training Programs
- "Unbreakable Valor" Book Release Honors the Power of Resilience
- AUACOM Signs a Statement of Shared Interest with BMCC
- Boston: New Pathways For Direct Entry For Madison Park Graduates Into Union Apprenticeship Programs
- WWSG Announces Exclusive Speaking Partnership with Patrick McGee, Author of 'Apple in China'
- Multi-Billion Dollar Drone Cleaning Market Addressed via New UAE Office, AI Drone and Quantum Computing Solutions in Varied Industries ZenaTech, Inc
- Boston: Improving Parking and Curb Usage Through Tech Innovation
- Timken to Participate in the KeyBanc Industrials & Basic Materials Conference